Pioglitazone Confers Neuroprotection Against Ischemia-Induced Pyroptosis due to its Inhibitory Effects on HMGB-1/RAGE and Rac1/ROS Pathway by Activating PPAR-ɤ
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
Pioglitazone Confers Neuroprotection Against Ischemia-Induced Pyroptosis due to its Inhibitory Effects on HMGB-1/RAGE and Rac1/ROS Pathway by Activating PPAR-ɤ ; volume:45 ; number:6 ; year:2018 ; pages:2351-2368
Cellular physiology and biochemistry ; 45, Heft 6 (2018), 2351-2368
- Creator
-
Xia, Pingping
Pan, Yundan
Zhang, Fan
Wang, Na
Wang, E.
Guo, Qulian
Ye, Zhi
- DOI
-
10.1159/000488183
- URN
-
urn:nbn:de:101:1-201805031952
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:49 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Xia, Pingping
- Pan, Yundan
- Zhang, Fan
- Wang, Na
- Wang, E.
- Guo, Qulian
- Ye, Zhi
Other Objects (12)
The PPAR-γ agonist pioglitazone modulates inflammation and induces neuroprotection in parkinsonian monkeys
![RAGE dependent regulation of PPAR-α [PPAR-alpha] in bone metabolism](/assets/placeholder/searchResultMediaNoDigitisedMedia.png)
RAGE dependent regulation of PPAR-α [PPAR-alpha] in bone metabolism
RAGE-deficiency results in reduced PPAR-α [PPAR-alpha] nuclear translocation, proinflammation and altered bone metabolism
Pioglitazone, a PPAR-y agonist, as one of the new therapeutic candidates for C3 glomerulopathy
Apoptosis rate and transcriptional response of pancreatic islets exposed to the PPAR gamma agonist Pioglitazone
The PPAR-gamma agonist pioglitazone protects cortical neurons from inflammatory mediators via improvement in peroxisomal function
Post-treatment with the PPAR-γ agonist pioglitazone inhibits inflammation and bacterial growth during Klebsiella pneumonia
The peroxisome proliferator-activated receptor (PPAR) alpha agonist fenofibrate maintains bone mass, while the PPAR gamma agonist pioglitazone exaggerates bone loss, in ovariectomized rats
Different skeletal effects of the peroxisome proliferator activated receptor (PPAR)α agonist fenofibrate and the PPARγ agonist pioglitazone
PPAR γ agonist pioglitazone partially reverses hyperglycemia but improves semen quality and testicular histomorphometrics in alloxan-induced diabetic rats
Pioglitazone and PPAR-γ modulating treatment in hypertensive and type 2 diabetic patients after ischemic stroke: a national cohort study
RAGE
The PPAR-γ agonist pioglitazone modulates inflammation and induces neuroprotection in parkinsonian monkeys
RAGE dependent regulation of PPAR-α [PPAR-alpha] in bone metabolism
RAGE-deficiency results in reduced PPAR-α [PPAR-alpha] nuclear translocation, proinflammation and altered bone metabolism
Pioglitazone, a PPAR-y agonist, as one of the new therapeutic candidates for C3 glomerulopathy
Apoptosis rate and transcriptional response of pancreatic islets exposed to the PPAR gamma agonist Pioglitazone
The PPAR-gamma agonist pioglitazone protects cortical neurons from inflammatory mediators via improvement in peroxisomal function
Post-treatment with the PPAR-γ agonist pioglitazone inhibits inflammation and bacterial growth during Klebsiella pneumonia
The peroxisome proliferator-activated receptor (PPAR) alpha agonist fenofibrate maintains bone mass, while the PPAR gamma agonist pioglitazone exaggerates bone loss, in ovariectomized rats
Different skeletal effects of the peroxisome proliferator activated receptor (PPAR)α agonist fenofibrate and the PPARγ agonist pioglitazone
PPAR γ agonist pioglitazone partially reverses hyperglycemia but improves semen quality and testicular histomorphometrics in alloxan-induced diabetic rats
Pioglitazone and PPAR-γ modulating treatment in hypertensive and type 2 diabetic patients after ischemic stroke: a national cohort study
RAGE
The PPAR-γ agonist pioglitazone modulates inflammation and induces neuroprotection in parkinsonian monkeys
RAGE dependent regulation of PPAR-α [PPAR-alpha] in bone metabolism
RAGE-deficiency results in reduced PPAR-α [PPAR-alpha] nuclear translocation, proinflammation and altered bone metabolism
Pioglitazone, a PPAR-y agonist, as one of the new therapeutic candidates for C3 glomerulopathy
Apoptosis rate and transcriptional response of pancreatic islets exposed to the PPAR gamma agonist Pioglitazone
The PPAR-gamma agonist pioglitazone protects cortical neurons from inflammatory mediators via improvement in peroxisomal function
Post-treatment with the PPAR-γ agonist pioglitazone inhibits inflammation and bacterial growth during Klebsiella pneumonia
The peroxisome proliferator-activated receptor (PPAR) alpha agonist fenofibrate maintains bone mass, while the PPAR gamma agonist pioglitazone exaggerates bone loss, in ovariectomized rats
Different skeletal effects of the peroxisome proliferator activated receptor (PPAR)α agonist fenofibrate and the PPARγ agonist pioglitazone
PPAR γ agonist pioglitazone partially reverses hyperglycemia but improves semen quality and testicular histomorphometrics in alloxan-induced diabetic rats
Pioglitazone and PPAR-γ modulating treatment in hypertensive and type 2 diabetic patients after ischemic stroke: a national cohort study